Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free SBTX Stock Alerts

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 9.58 +0.08 (+0.84%)
As of 11:36 AM Eastern
Compare

SBTX vs. MPH, FARN, 4BB, POLB, and REDX

Should you buy SkinBioTherapeutics stock or one of its competitors? SkinBioTherapeutics's main competitors and comparable companies include Mereo BioPharma Group plc (MPH.L) (MPH), Faron Pharmaceuticals Oy (FARN), 4basebio (4BB), Poolbeg Pharma (POLB), and Redx Pharma (REDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SkinBioTherapeutics compare to Mereo BioPharma Group plc (MPH.L)?

SkinBioTherapeutics (LON:SBTX) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

Mereo BioPharma Group plc (MPH.L) has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M4.75-£3.71M-£0.16N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

3.0% of SkinBioTherapeutics shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Mereo BioPharma Group plc (MPH.L) Neutral

Summary

SkinBioTherapeutics and Mereo BioPharma Group plc (MPH.L) tied by winning 4 of the 8 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Faron Pharmaceuticals Oy?

SkinBioTherapeutics (LON:SBTX) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

SkinBioTherapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M4.75-£3.71M-£0.16N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

3.0% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by company insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 0 mentions for SkinBioTherapeutics. Faron Pharmaceuticals Oy's average media sentiment score of 0.34 beat SkinBioTherapeutics' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Faron Pharmaceuticals Oy Neutral

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

SkinBioTherapeutics has a beta of 0.107, meaning that its stock price is 89% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.121, meaning that its stock price is 12% more volatile than the broader market.

Summary

Faron Pharmaceuticals Oy beats SkinBioTherapeutics on 7 of the 12 factors compared between the two stocks.

How does SkinBioTherapeutics compare to 4basebio?

4basebio (LON:4BB) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

4basebio has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
SkinBioTherapeutics -8.73%-5.25%-61.18%

4basebio has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market.

4basebio presently has a consensus price target of GBX 1,400, suggesting a potential upside of 185.77%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts clearly believe 4basebio is more favorable than SkinBioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
SkinBioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

SkinBioTherapeutics has higher revenue and earnings than 4basebio. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.69M44.81-£9.84M-£109.00N/A
SkinBioTherapeutics£5.23M4.75-£3.71M-£0.16N/A

In the previous week, 4basebio's average media sentiment score of 0.30 beat SkinBioTherapeutics' score of 0.00 indicating that 4basebio is being referred to more favorably in the media.

Company Overall Sentiment
4basebio Neutral
SkinBioTherapeutics Neutral

0.9% of 4basebio shares are held by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

4basebio beats SkinBioTherapeutics on 10 of the 15 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

SkinBioTherapeutics has higher revenue and earnings than Poolbeg Pharma. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
SkinBioTherapeutics£5.23M4.75-£3.71M-£0.16N/A

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
SkinBioTherapeutics Neutral

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Poolbeg Pharma has a beta of 1.802, suggesting that its share price is 80% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market.

Poolbeg Pharma has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Summary

Poolbeg Pharma and SkinBioTherapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Redx Pharma?

Redx Pharma (LON:REDX) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Redx Pharma has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Redx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Redx PharmaN/A -180.80% -43.95%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Redx Pharma has a beta of -0.53, suggesting that its share price is 153% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market.

In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Redx Pharma Neutral
SkinBioTherapeutics Neutral

SkinBioTherapeutics has higher revenue and earnings than Redx Pharma. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A
SkinBioTherapeutics£5.23M4.75-£3.71M-£0.16N/A

72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Redx Pharma and SkinBioTherapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSkinBioTherapeuticsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£24.62M£3.99B£7.20B£2.89B
Dividend YieldN/A3.61%2.53%6.17%
P/E Ratio-59.8812.25272.63364.82
Price / Sales4.751,349.92620.8183,676.90
Price / Cash9.00105.2976.9827.89
Price / Book5.7116.1912.856.75
Net Income-£3.71M-£22.72M£3.47B£5.89B
7 Day Performance-1.24%-1.18%-0.22%-0.78%
1 Month Performance-14.08%12.75%8.04%2.38%
1 Year Performance-32.63%53.86%25.08%22.66%

SkinBioTherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 9.58
+0.8%		N/A-34.6%£24.62M£5.23MN/A11
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
FARN
Faron Pharmaceuticals Oy
N/AGBX 40.11
-1.0%		N/A-80.6%£81.38MN/AN/A34
4BB
4basebio
1.6254 of 5 stars		GBX 485
+4.3%		GBX 1,400
+188.7%		-43.2%£75.10M£1.69MN/A101
POLB
Poolbeg Pharma
N/AGBX 8.82
-2.0%		N/A+160.1%£67.31MN/AN/A12

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SBTX) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
Under $1… and Wall Street already knows about it
On August 19th, Bitcoin exploded 23% in a matter of days… triggering nearly $3 billion in short liquidations, ...
Crypto 101 Media | Sponsoredtc pixel
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Why Boston Ships In Natural Gas It Already Has at Home
A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...
Porter & Company | Sponsoredtc pixel
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel